Analysis has confirmed the Asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant.
MIR Research analysis identified 59 first-in-class programs in the asthma pipeline, acting on 43 first-in-class molecular targets, accounting for 23% of all products with a disclosed molecular target and reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as, despite the high clinical trial attrition rate, it is highly likely that many of the first-in-class technologies will reach the market over the coming decade and may transform the clinical and commercial landscape.
While the current Asthma Market is almost exclusively dominated by small molecules, which account for approximately 99% (the exception being Xolair), the current asthma pipeline includes 64 biologics, accounting for 24%. Small molecules amount to 178 compounds, equating to 66%.

[b]Check Complete Report @[/b] http://www.marketintelreports.com/report/gbihc359mr/frontier-pharma-asthma--identifying-and-commercializing-first-in-class-innovation

[b]Scope of the Report:[/b]
The report analyzes innovation in asthma in the context of the overall pipeline and the current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in asthma, and pinpoints opportunities for in-licensing. The report covers and includes -
•A brief introduction to asthma, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms
•The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline
•Comprehensive review of the pipeline for first-in-class therapies, analyzed by of stage of development, molecule type, and molecular target
•Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets
•Assessment of the licensing and co-development deal landscape for asthma therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products

[b]Get Sample Brochure of the Report @[/b] http://www.marketintelreports.com/pdfdownload.php?id=gbihc359mr

[b]Reasons to Buy:[/b]
The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to -
•Understand the focal shifts in molecular targets in the asthma pipeline
•Understand the distribution of pipeline programs by phase of development, molecule type and molecular target
•Access a scientific and clinical analysis of first-in-class developmental programs for asthma, benchmarked against non-first-in-class targets
•Access a list of the first-in-class therapies potentially open to deal-making opportunities

[b]Order a copy of Asthma Market Report @[/b] http://www.marketintelreports.com/purchase.php?id=gbihc359mr

[b]About us:[/b]
[b]MarketIntelReports (MIR)[/b] aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.
[b]MIR[/b] intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
[b]MarketIntelReports[/b] currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

[b]Contact us: [/b]
[b]Mayur S[/b]
Sales Manager
2711 Centerville Road, Suite 400,
Wilmington,
Delaware,
19808
United States
www.marketintelreports.com
[email protected]
Telephone: 1-302-684-6088